Colloidal dispersions for the delivery of acyclovir: A comparative study

Indian Journal of Pharmaceutical Sciences

Volumn 73, Issue 6, 2011, Pages 687-693

  Cortesi, Rita ^a   Ravani, Laura ^a   Menegatti, Enea ^a   Drechsler, M ^b   Esposito, Elisabetta ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

Acyclovir; antiviral activity; ethosomes; HSV 1; SLN

Indexed keywords

ACICLOVIR; ALCOHOL; DRUG CARRIER; ETHOSOME; PHOSPHATIDYLCHOLINE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; COLLOID; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DISPERSION; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; HERPES SIMPLEX VIRUS 1; MONOLAYER CULTURE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; VERO CELL; VIRUS PLAQUE; ZETA POTENTIAL;

EID: 84866247705     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.100253     Document Type: Article

References (29)

1. Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1983;26:378-438.
2. Whitley RJ. Herpes simplex virus infection. Semin Pediatr Infect Dis 2002;13:6-11.
3. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115-33.
4. Blum MR, Liao SH, Miranad PD. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 1982;73:186-92.
5. Modiano P, Salloum E, Gillet-Terver MN, Barbaud A, Georges JC, Thouvenot D, et al. Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrom. Br J Dermatol 1995;133:475-8.
6. Kaufman HE. Treatment of viral diseases of the cornea and external eye. Prog Retin Eye Res 2000;19:69-85.
7. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes-novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000;65:403-18.
8. Touitou E, Godin B, Dayan N, Weiss C, Piliponsky A, Levi-Schaffer F. Intracellular delivery mediated by an ethosomal carrier. Biomaterials 2001;22:3053-9.
9. Touitou E. Drug delivery across the skin. Exp Opin Biol Ther 2002;2:723-33.
10. Touitou E, Godin B. Dermal drug delivery with ethosomes: Therapeutic potential. Therapy 2007;4:465-72.
11. Godin B, Touitou E. Ethosomes: New prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst 2003;20:63-72.
12. Jain S, Tiwary AK, Sapra B, Jain NK. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech 2007;8:E111.
13. Bendas ER, Tadros MI. Enhanced transdermal delivery of salbutamol sulfate via ethosomes. AAPS PharmSciTech 2007;8:E107.
14. Horwitz E, Pisanty S, Czerninski R, Helser M, Eliav E, Touitou E. A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:700-5.
15. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled delivery-A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
16. Bunjes H, Drechsler M, Koch MH, Westesen K. Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharm Res 2001;18:287-93.
17. Westesen K, Bunjes H, Koch MH. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997;48:223-33.
18. Westesen K, Siekmann B. Biodegradable colloidal drug carrier systems based on solid lipids. In: Benita S, editor. Microencapsulation. New York: Marcel Dekker; 1996. p. 213-58.
19. Lippacher A, Muller RH, Mader K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm 2001;214:9-12.
20. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable size produced by a rapid extrusion procedure. Biochim Biophys Acta 1986;858:161-8.
21. Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res 2008;25:1521-30.
22. Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001;47: 165-96.
23. Nastruzzi C, Esposito E, Pastesini C, Gambari R, Menegatti E. Comparative study on the release kinetics of methyl nicotinate from topic formulations. Int J Pharm 1993;90:43-50.
24. Esposito E, Menegatti E, Cortesi R. Ethosomes and liposomes as topical vehicles for azelaic acid: A preformulatory study. J Cosmet Sci 2004;55:253-64.
25. Shah PV, Elkins JS, Hanus J, Noorizadeh C, Skelly JP. In vitro release of hydrocortisone from topical preparations and automated procedure. Pharm Res 1991;8:55-9.
26. Nastruzzi C, Esposito E, Pastesini C, Gambari R, Menegatti E. Comparative study on the release kinetics of methyl-nicotinate from topic formulations. Int J Pharm 1993;90:43-50.
27. Hill EL, Ellis MN, Nguyen DP. Antiviral and antiparasitic susceptibility testing. In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, editors. Manual of Clinical Microbiology. 5th ed. Washinton DC: American Society for Microbiology; 1991.p. 1184-91.
28. Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, Parish ML, et al. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res 1998;40: 85-94.
29. Walro DG, Rosenthal KS. The antiviral xanthate compound D609 inhibits herpes simplex virus type 1 replication and protein phosphorylation. Antiviral Res 1997;36:63-72.